EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY 4.0

Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis

Jeffrey B Locke iD, Chris M Pillar, Mariana Castanheira iD, Cecilia G Carvalhaes, David Andes iD, Jalal A Aram iD, Christina Andrzejewski, Ken Bartizal, Anita F Das, Taylor Sandison, George R Thompson, Peter G Pappas

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.01584-23 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Jeffrey B Locke und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cidara Therapeutics, Inc., San Diego, California, USA. Hauptthemen laut MEDLINE: Antifungal Agents, Candidemia, Candidiasis, Invasive, Caspofungin. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rezafungin is a long-acting, intravenously administered echinocandin for the treatment of candidemia and invasive candidiasis (IC). Non-inferiority of rezafungin vs caspofungin for the treatment of adults with candidemia and/or IC was demonstrated in the Phase 3 ReSTORE study based on the primary endpoints of day 14 global cure and 30-day all-cause mortality. Here, an analysis of ReSTORE data evaluating efficacy outcomes by baseline Candida species is described. Susceptibility testing was performed for Candida species using the Clinical and Laboratory Standards Institute reference broth microdilution method. There were 93 patients in the modified intent-to-treat population who received rezafungin; 94 received caspofungin. Baseline Candida species distribution was similar in the two treatment groups; C. albicans (occurring in 41.9% and 42.6% of patients in the rezafungin and caspofungin groups, respectively), C. glabrata (25.8% and 26.6%), and C. tropicalis (21.5% and 18.1%) were the most common pathogens. Rates of global cure and mycological eradication at day 14 and day 30 all-cause mortality by Candida species were comparable in the rezafungin and caspofungin treatment groups and did not appear to be impacted by minimal inhibitory concentration (MIC) values for either rezafungin or caspofungin. Two patients had baseline isolates with non-susceptible MIC values (both in the rezafungin group: one non-susceptible to rezafungin and one to caspofungin, classified as intermediate); both were candidemia-only patients in whom rezafungin treatment was successful based on the day 30 all-cause mortality endpoint. This analysis of ReSTORE demonstrated the efficacy of rezafungin for candidemia and IC in patients infected with a variety of Candida species.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsCandidemiaCandidiasis, InvasiveCaspofunginEchinocandinsMicrobial Sensitivity TestsAdultAgedFemaleHumansMaleMiddle AgedCandidaCandida albicansCandida glabrataCandida tropicalisLipopeptidesTreatment Outcome

Stichwörter der Autor:innen

Candida speciesantifungal therapycandidemiaechinocandininvasive candidiasis

Substanzen

Antifungal AgentsCaspofunginEchinocandinsLipopeptidesRezafungin

Autor:innen und Institutionen

  • Cidara Therapeutics, Inc., San Diego, California, USA.
  • Science and Operations, Microbiologics, Kalamazoo, Michigan, USA.
  • JMI Laboratories, North Liberty, Iowa, USA.
  • Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Medical Affairs, Melinta Therapeutics, LLC, Parsippany, New Jersey, USA.
  • Division of Infectious Diseases, Department of Internal Medicine and Department of Medical Microbiology and Immunology, University of California Davis Medical Center, Sacramento, California, USA.

ORCID-Profile: Jeffrey B Locke, Mariana Castanheira, David Andes, Jalal A Aram

Zitieren

APA

Locke, J. B., Pillar, C. M., Castanheira, M., Carvalhaes, C. G., Andes, D., Aram, J. A., Andrzejewski, C., Bartizal, K., Das, A. F., Sandison, T., Thompson, G. R., & Pappas, P. G. (2024). Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01584-23

Vancouver

Locke JB, Pillar CM, Castanheira M, Carvalhaes CG, Andes D, Aram JA, et al. Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01584-23

BibTeX
@article{Locke2024,
  author = {Locke, Jeffrey B and Pillar, Chris M and Castanheira, Mariana and Carvalhaes, Cecilia G and Andes, David and Aram, Jalal A and Andrzejewski, Christina and Bartizal, Ken and Das, Anita F and Sandison, Taylor and Thompson, George R and Pappas, Peter G},
  title = {Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.01584-23}
}
Kostenlos starten →